Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...
Shares in major pharmaceutical companies are down as well: Pfizer has fallen 4.6 percent, Eli Lilly 4.2 percent, Amgen ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...
Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...
Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...
Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback